ERBB2 and breast carcinoma: The two most important questions in therapy of early breast cancer to be resolved over the next decade are: Who can safely be spared adjuvant chemotherapy? and Who has the maximum benefit from chemo-, endocrine and/or anti-HER2 therapy?